Targeted Nanoparticle Therapy for Erectile Dysfunction
Localized SDF-1 mRNA nanoparticle delivery for treating erectile dysfunction.
['FUNDING_R01'] · UNIVERSITY OF MARYLAND BALTIMORE · NIH-11083687
This research explores a new way to deliver a healing molecule using tiny particles to help men with erectile dysfunction.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MARYLAND BALTIMORE (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11083687 on ClinicalTrials.gov |
What this research studies
Erectile dysfunction (ED) affects millions of men, and current medications often fall short or cause unwanted side effects. This project is developing a new way to treat ED by delivering a special healing molecule, SDF-1, directly to the affected area using tiny nanoparticles. SDF-1 has shown in animal models that it can help regenerate blood vessels, nerves, and muscles in the penis, which are crucial for erectile function. By repairing these tissues and activating the body's natural healing pathways, this targeted therapy aims to restore natural erectile function more effectively. This could provide a much-needed alternative for those who don't respond to existing treatments.
Who could benefit from this research
Good fit: This research is ultimately intended for men who experience erectile dysfunction, especially those for whom current oral medications are ineffective or cause side effects.
Not a fit: Patients without erectile dysfunction would not receive direct benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this therapy could offer a more effective and long-lasting treatment for erectile dysfunction by directly repairing damaged tissues, potentially improving quality of life for many men.
How similar studies have performed: While SDF-1 has shown promise in animal models for regenerating tissues related to erectile function, this specific nanoparticle delivery method is a novel approach currently being developed.
Where this research is happening
BALTIMORE, UNITED STATES
- UNIVERSITY OF MARYLAND BALTIMORE — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUK, JUNG SOO — UNIVERSITY OF MARYLAND BALTIMORE
- Study coordinator: SUK, JUNG SOO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.